Tag Archives: GLP-1 receptor agonists

Why do some patients still face heart risks even after managing blood sugar and cholesterol? This lingering issue has led researchers to explore how GLP-1 therapies may influence cardiovascular inflammation as a possible missing link. While traditional treatments focus on glucose and lipid control, growing evidence suggests inflammation may continue …

When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …

GLP-1 receptor agonists have reshaped the management of type 2 diabetes and obesity. However, growing interest now surrounds the potential role of GLP-1 therapy in normal-weight patients with cardiometabolic risk and whether treatment decisions should rely less on BMI alone. While body mass index remains a widely used screening tool, …

GLP-1 receptor agonists have transformed diabetes care, but the long-term safety of GLP-1 therapies has become an important topic as treatment continues for many years. Initially, clinicians prescribed these medications primarily for glycemic control in patients with type 2 diabetes. However, their role has expanded due to additional benefits in …

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

Weight loss conversations often focus on a simple question: how much lean mass is preserved? However, emerging research suggests that the story is more complex. GLP-1 receptor agonists are well known for promoting weight loss and improving glycemic control, but scientists are increasingly examining how these medications influence muscle health …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity. However, one question clinicians increasingly ask is whether gastric motility adapts during long-term GLP-1 therapy. These medications slow gastric emptying, which contributes to appetite control and postprandial glucose reduction. Yet the human body often …

GLP-1 receptor agonists have transformed diabetes and obesity treatment, yet safety questions still surface in clinic visits. One concern continues to appear in patient discussions: thyroid cancer risk. The topic often traces back to early rodent studies that triggered boxed warnings for medullary thyroid carcinoma (MTC). However, clinicians today rely …

GLP-1 receptor agonists and dual incretin therapies are transforming diabetes care. These medications often produce significant and rapid improvements in glycemic control, sometimes lowering A1C levels faster than traditional treatments. However, clinicians have begun asking an important question: could rapid A1C reduction with GLP-1 therapy increase retinopathy risk in some …

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …